Cost-effectiveness of one year dementia follow-up care by memory clinics or general practitioners: economic evaluation of a randomised controlled trial

Els Meeuwsen, René Melis, Geert van der Aa, Gertie Golüke-Willemse, Benoit de Leest, Frank van Raak, Carla Schölzel-Dorenbos, Desiree Verheijen, Frans Verhey, Marieke Visser, Claire Wolfs, Eddy Adang, Marcel Olde Rikkert, Els Meeuwsen, René Melis, Geert van der Aa, Gertie Golüke-Willemse, Benoit de Leest, Frank van Raak, Carla Schölzel-Dorenbos, Desiree Verheijen, Frans Verhey, Marieke Visser, Claire Wolfs, Eddy Adang, Marcel Olde Rikkert

Abstract

Objective: To evaluate the cost-effectiveness of post-diagnosis dementia treatment and coordination of care by memory clinics compared to general practitioners' care.

Methods: A multicentre randomised trial with 175 community dwelling patients newly diagnosed with mild to moderate dementia, and their informal caregivers, with twelve months' follow-up. Cost-effectiveness was evaluated from a societal point of view and presented as incremental cost per quality adjusted life year. To establish cost-effectiveness, a cost-utility analysis was conducted using utilities based on the EQ-5D. Uncertainty surrounding the incremental cost-effectiveness ratio (difference in costs divided by difference in effects) was calculated by bootstrapping from the original data.

Results: Compared to general practitioners' care, treatment by the memory clinics was on average €1024 (95% CI: -€7723 to €5674) cheaper, and showed a non-significant decrease of 0.025 (95% CI: -0.114 to 0.064) quality adjusted life years. The incremental cost-effectiveness point estimate from the bootstrap simulation was € 41 442 per QALY lost if one would use memory clinic care instead of general practitioner care.

Conclusion: No evidence was found that memory clinics were more cost-effective compared to general practitioners with regard to post-diagnosis treatment and coordination of care of patients with dementia in the first year after diagnosis.

Trial registration: ClinicalTrials.gov NCT00554047.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Scatterplot of the estimated incremental…
Figure 1. Scatterplot of the estimated incremental costs and incremental effects obtained by bootstrap simulations.
Figure 2. Cost-effectiveness acceptability curve.
Figure 2. Cost-effectiveness acceptability curve.
The probability that the Memory Clinic was cost-effective compared with the General Practitioner (solid line). The dotted line shows the curve if only the QALY of the patient as rated by the caregiver was used. The striped and the stripe-dot line show the probability if the cost and QALY of the patient alone and if the cost and QALY of the caregiver alone (cost of the caregiver being caregiving time and productivity loss) were used respectively.

References

    1. Jonsson L, Wimo A (2009) The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics., 27, 391–403.
    1. Wimo A, Winblad B, Jonsson L (2010) The worldwide societal costs of dementia: Estimates for 2009. Alzheimers. Dement., 6, 98–103.
    1. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al... (2012) Clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N. Engl. J. Med., 367, 795–804.
    1. Alzeimer Europe (2012) Available: .Accessed 2013 Oct 11.
    1. Burns A, Robert P (2009) The National Dementia strategy in England. BMJ, 338, b931.
    1. Cahill S (2010) Developing a national dementia strategy for Ireland. Int. J. Geriatr. Psychiatry, 25, 912–916.
    1. Department of Health (2009) Living well with dementia: a National Dementia Strategy. London: Department of Health website. Available: . Accessed 2013 Oct 11.
    1. Eriksson S (2010) Developments in dementia strategy. Int. J. Geriatr. Psychiatry, 25, 885–886.
    1. Jolley D, Benbow SM, Grizzell M (2006) Memory clinics. Postgrad. Med. J., 82, 199–206.
    1. Passmore AP, Craig DA (2004) The future of memory clinics. Psychiatric Bulletin, 28, 375–377.
    1. Ramakers IH, Verhey FR (2011) Development of memory clinics in the Netherlands: 1998 to 2009. Aging Ment. Health, 15, 34–39.
    1. Wolfs CA, Dirksen CD, Kessels A, Severens JL, Verhey FR (2009) Economic evaluation of an integrated diagnostic approach for psychogeriatric patients: results of a randomized controlled trial. Arch. Gen. Psychiatry, 66, 313–323.
    1. Melis RJ, Meeuwsen EJ, Parker SG, Olde Rikkert MGM (2009) Are memory clinics effective? The odds are in favour of their benefit, but conclusive evidence is not yet available. J. R. Soc. Med., 102, 456–457.
    1. Knapp M, Iemmi V, Romeo R (2012) Dementia care costs and outcomes: a systematic review. Int. J. Geriatr. Psychiatry, DOI:
    1. Meeuwsen EJ, Melis RJ, Van Der Aa GCHM, Goluke-Willemse GAM, De Leest BJM, et al... (2012) Effectiveness of dementia follow-up care by memory clinics or general practitioners: randomised controlled trial. BMJ, 344, e3086.
    1. Meeuwsen EJ, Melis RJ, Adang EM, Goluke-Willemse GA, Krabbe PF, et al... (2009) Cost-effectiveness of post-diagnosis treatment in dementia coordinated by Multidisciplinary Memory Clinics in comparison to treatment coordinated by general practitioners: an example of a pragmatic trial. J. Nutr. Health Aging, 13, 242–248.
    1. Richtlijn CBO (2005) Diagnostiek en medicamenteuze behandeling van dementie Alphen aan den Rijn, (in Dutch).
    1. Boomsma LJ, De Bont M, Engelsman C, Gussekloo J, Hartman C, et al... (2005) Landelijke Eerstelijns Samenwerkings Afspraak Dementie. Huisarts Wet, 48, 124–126 (in Dutch).
    1. Nederlands Huisartsen Genootschap (2003) NHG-Standaard Dementie M21 (in Dutch).
    1. Jonsson L, Andreasen N, Kilander L, Soininen H, Waldemar G, et al... (2006) Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis. Assoc. Disord., 20, 49–55.
    1. Lamers LM, Stalmeier PF, McDonnell J, Krabbe PF, van Busschbach JJ (2005) [Measuring the quality of life in economic evaluations: the Dutch EQ-5D tariff]. Ned. Tijdschr. Geneeskd., 149, 1574–1578.
    1. Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ (2006) The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ., 15, 1121–1132.
    1. Dolan P (1997) Modeling valuations for EuroQol health states. Med. Care, 35, 1095–1108.
    1. Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005) Methods for the economic evaluation of health care programmes. (Third ed.) Oxford University Press.
    1. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH (2004) Handleiding voor kostenonderzoek; Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie 2004 College voor zorgverzekeringen (CVZ) (in Dutch).
    1. CBS (2009) Statistics Netherlands website. Available: . Accessed 2013 Oct 11.
    1. Wimo A, Nordberg G (2007) Validity and reliability of assessments of time. Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument. Arch. Gerontol. Geriatr., 44, 71–81.
    1. van Hout BA, Al MJ, Gordon GS, Rutten FF (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Econ., 3, 309–319.
    1. Folstein MF, Folstein SE, McHugh PR (1975) Mini-Mental State - Practical Method for Grading Cognitive State of Patients for Clinician. Journal of psychiatric research, 12, 189–198.
    1. Miller MD, Paradis CF, Houck PR, Mazumdar S, Stack JA, et al... (1992) Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res., 41, 237–248.
    1. Graff MJ, Adang EM, Vernooij-Dassen MJ, Dekker J, Jonsson L, et al... (2008) Community occupational therapy for older patients with dementia and their care givers: cost effectiveness study. BMJ, 336, 134–138.
    1. Krol M, Brouwer W, Sendi P (2006) Productivity costs in health-state valuations : does explicit instruction matter? Pharmacoeconomics 24, 401–414.
    1. U.S.Department of Health and Human Services (2012) National Plan to address Alzheimer’s disease - National Alzheimer’s Project Act (NAPA). Alzheimers. Dement., 8, 234–236.
    1. World Health Organization, Alzheimer’s Disease International (2012) Dementia: a public health priority WHO press.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever